Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Letters: More on the History of Polymyalgia Rheumatica and Giant Cell Arteritis

Charles Plotz, MD, and William P. Docken, MD  |  Issue: May 2013  |  May 1, 2013

I just got the March 2013 article with the nice cover portrait of Giamberti and his temporal artery. The accompanying article by your colleague William Docken was excellent, too, but not quite complete.

Of course the syndrome of PMR and giant-cell arteritis was well known long before Barber named it, but was completely ignored in the U.S. literature until there was a single case report by Calabro that was followed by the report of 11 cases from my clinic at Mount Sinai Hospital in New York (Davison S, Spiera H, and Plotz C.M. Arthritis Rheum. 1966;9:18–23). Articles on treatment followed.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

It has always been gratifying to note that more recent years have spurred interest in this syndrome by Andy Healey, Gene Hunder, and many others. It is strange that the first published report did not appear until ours in 1966.

Charles Plotz, MD

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Emeritus Professor of Medicine SUNY Health Science Center, Brooklyn, N.Y.

Dr. Docken Weighs In

Thank you for your e-mail. Constraints of space did not permit me to provide a fuller history of PMR/GCA, and to acknowledge all of those in the field who have brought these diseases to the attention of the rheumatologic community. I cited Barber not as the first doctor who recognized PMR, but as the one who, I believe, first coined the term (based on the mistaken notion—he was a neurologist!—that PMR was a condition of the muscles, rather than of the joints and bursae). You are correct that John Calabro was the first to author a paper on the topic from this side of the Atlantic, followed not long after by your paper.

It is indeed strange that it took quite so long for PMR/GCA to emerge into rheumatologic consciousness; Arthur Hall, a long-time member of our division, who recently died, used to muse, apropos of PMR, while puffing on his ever-present pipe, “I wonder what we used to call this years ago… .” Man sieht nur was man weiß, as Goethe opined.

I do think that Andy Healey’s correct insistence on PMR as a disorder of joints in the 1980s and early 1990s has been underrecognized. I have a hand-written note from Dr. Healey dating from 1989—still affixed to the bulletin board in my office—in response to a rather minor article of mine in the old Rheumatic Disease Clinics of North America on the uses of low-dose prednisone, where I discussed PMR as disorder of joints and referenced several of Dr. Healey’s publications. In his letter, Dr. Healey thanked me for the article, and—rather poignantly, I have always thought—added, “For a long time, it seemed no one was listening.”

Page: 1 2 | Single Page
Share: 

Filed under:ConditionsVasculitis Tagged with:Giant Cell ArteritisPolymyalgia Rheumatica

Related Articles

    Two Inflammatory Conditions—Polymyalgia Rheumatica and Giant Cell Arteritis—Share Clinical Connection

    March 1, 2013

    Polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) have common clinical and epidemiologic links, but they need not occur synchronously

    Polymyalgia Rheumatica: New Tricks for an Old Disease

    January 29, 2024

    Originally posted Feb. 13, 2023; reposted in conjunction with publication of the PMR supplement to the February 2024 issue of The Rheumatologist. PHILADELPHIA—Polymyalgia rheumatica (PMR) is a chronic inflammatory condition that almost exclusively affects individuals older than 50.1 First described in 1888, PMR has been a recognized rheumatic disease since at least 1957. Diagnosing the…

    Permanent Vision Loss in Late Giant Cell Arteritis

    October 18, 2018

    Patients with polymyalgia rheumatica (PMR) or peripheral arthritis may require extra vigilance during treatment because of a suspected link to giant cell arteritis (GCA) and, potentially, permanent vision loss. “Development of giant cell arteritis after treating polymyalgia or peripheral arthritis: a retrospective case-control study,” a March 2018 study published in The Journal of Rheumatology, suggests…

    How to Manage Polymyalgia Rheumatica

    December 16, 2015

    Recognizing the need to provide guidance on the current disparate management of polymyalgia rheumatica (PMR), the American College of Rheumatology (ACR), in collaboration with the European League Against Rheumatism (EULAR), recently published the first international set of recommendations for the screening, treatment and management of PMR.1,2 Specifically, the recommendations offer guidance on the use of…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences